Benzbromarone showed no clear difference in acute gout attacks compared with allopurinol (low certainty).
Benzbromarone may leads to lower withdrawal due to adverse events compared with probenecid (low certainty).
Benzbromarone may leads to lower total adverse events compared with probenecid (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Benzbromarone showed no clear difference in serum urate normalisation compared with allopurinol (moderate certainty).
Benzbromarone showed no clear difference in withdrawal due to adverse events compared with allopurinol (low certainty).
Benzbromarone showed no clear difference in total adverse events compared with allopurinol (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Benzbromarone showed no clear difference in acute gout attacks compared with probenecid (low certainty).
Benzbromarone probably leads to higher serum urate normalisation ≤ 5 mg/dL (≤ 0.3 mmol/L) compared with probenecid (moderate certainty).
Allopurinol showed no clear difference in acute gout attacks compared with benzbromarone (low certainty).
Allopurinol showed no clear difference in proportion achieving target serum urate compared with benzbromarone (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Allopurinol showed no clear difference in withdrawal due to adverse events compared with benzbromarone (low certainty).